Jessica Serra - Revance Head ESG
| RVNC Stock | USD 3.73 0.12 3.32% |
Insider
Jessica Serra is Head ESG of Revance
| Address | 1222 Demonbreun Street, Nashville, TN, United States, 37203 |
| Phone | 615 724 7755 |
| Web | https://www.revance.com |
Revance Management Efficiency
The company has return on total asset (ROA) of (0.2436) % which means that it has lost $0.2436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance's management efficiency ratios could be used to measure how well Revance manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.24, whereas Return On Tangible Assets are forecasted to decline to (0.73). At present, Revance's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 12.3 M, whereas Total Assets are forecasted to decline to about 331.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Timothy Rolph | Akero Therapeutics | 70 | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| Rami Elghandour | Arcellx | 45 | |
| Brian MBA | Immunocore Holdings | 57 | |
| Quoc LeNguyen | 89bio Inc | 56 | |
| Rebecca MD | Madrigal Pharmaceuticals | 72 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Amanda Hill | 89bio Inc | N/A | |
| Rik Derynck | Pliant Therapeutics | N/A | |
| Harry MD | 89bio Inc | 59 | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| Mike Ouimette | Pliant Therapeutics | 51 | |
| Remy Sukhija | Madrigal Pharmaceuticals | 52 | |
| Prof Shair | Nuvalent | 55 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Melissa Abel | 89bio Inc | N/A | |
| Ryan Martins | 89bio Inc | 45 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Johannes Hull | Pliant Therapeutics | 49 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
Management Performance
| Return On Equity | -20.97 | ||||
| Return On Asset | -0.24 |
Revance Leadership Team
Elected by the shareholders, the Revance's board of directors comprises two types of representatives: Revance inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revance. The board's role is to monitor Revance's management team and ensure that shareholders' interests are well served. Revance's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revance's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dwight JD, Chief Counsel | ||
| Dustin Sjuts, Vice President of Strategy and Sales | ||
| Conor Gallagher, Head Aesthetics | ||
| Jeanie Herbert, Sr. Director of Investor Relations | ||
| Mark Foley, CEO Director | ||
| Erica Jordan, Chief Officer | ||
| Azita Nejad, VP Operations | ||
| Dwight Moxie, Chief Counsel | ||
| Justin Ford, VP People | ||
| Amie Krause, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Jessica Serra, Head ESG | ||
| Aubrey Rankin, Consultant | ||
| Tobin Schilke, CFO and Principal Financial Officer | ||
| Taryn Conway, Vice President of Marketing |
Revance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revance a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.97 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (0.72) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 678.07 M | ||||
| Shares Outstanding | 104.9 M | ||||
| Shares Owned By Insiders | 8.51 % | ||||
| Shares Owned By Institutions | 81.79 % | ||||
| Number Of Shares Shorted | 12.21 M | ||||
| Price To Earning | (7.60) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revance offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Revance's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Revance Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Revance Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revance. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Revance Stock refer to our How to Trade Revance Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revance. If investors know Revance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revance listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.34) | Revenue Per Share 2.656 | Quarterly Revenue Growth 0.107 | Return On Assets (0.24) | Return On Equity (20.97) |
The market value of Revance is measured differently than its book value, which is the value of Revance that is recorded on the company's balance sheet. Investors also form their own opinion of Revance's value that differs from its market value or its book value, called intrinsic value, which is Revance's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revance's market value can be influenced by many factors that don't directly affect Revance's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revance's value and its price as these two are different measures arrived at by different means. Investors typically determine if Revance is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revance's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.